

Overview

Syneron Medical Ltd. (NASDAQ: ELOS) manufactures and distributes medical aesthetic devices that are powered by the Company's proprietary, patented elos combined-energy technology of Bi-Polar Radio Frequency and Light. The Company's innovative elos technology provides the foundation for highly effective, safe and cost-effective systems that enable physicians to provide advanced solutions for a broad range of medical-aesthetic applications for both facial applications (including skin rejuvenation, wrinkle reduction, and skin tightening), and body shaping where the Company maintains a leadership position with its powerful VelaShape™ platform for circumferential reduction and cellulite treatment, and LipoLite™, Syneron's first device in the market for laser-assisted lipolysis.

Syneron has a proven track record of product innovation with five product families launched since 2001 and the company maintains a robust pipeline. The installed base of Syneron's platforms now numbers over 10,000 units worldwide .

The corporate, R&D, and manufacturing headquarters for Syneron Medical Ltd. is located in Israel. Syneron has offices and distributors throughout the world, including North American Headquarters in Canada, North American Logistics Support Center in Irvine, CA, European Headquarters in Germany, and Asia-Pacific Headquarters in Hong Kong, which provide sales, service and support.

Market Data

(as of February 2, 2009)

Ticker Symbol(NASDAQ)	ELOS
Recent price	\$7.02
52 week range	\$5.88 - \$18.04
Shares outstanding	27.5 million
Market Cap	\$193 million

Financial Highlights

(\$ in millions except per share data)


Income Statement	3Q08	3Q07
Revenues	28.5	33.1
Net Income	2.2	8.0
eps (fully diluted)	0.08	0.28

Balance Sheet	9/30/08	12/31/08
Cash & equivalents	218.7	203.8
Total assets	290.2	269.3
Shareholders' equity	254.4	230.8

Investment Highlights

- elōs technology provides superior, repeatable results with enhanced safety
- Significantly lower COGS than competition as gross margins are 75%, which is approx. 20% above industry average
- Broadest portfolio in the industry and approx. 20% market share in the USA and Worldwide
- Rapid ROI to doctors as the initial investment is recuperated in 12-18 months
- Exceptional customer responsiveness with guaranteed depot service
- Financial position: approx. \$220 million in cash with over \$170 million created from operations and zero debt

Sales by Geographical Area (Q3 2008)






Consistent Revenue Growth Across All

Markets

(U.S. \$ in millions)



Management

- Shimon Eckhouse
- Louis Scafuri
- Fabian Tenenbaum
- Rami Sharon
- Boris Vaynberg
- Yoni Iger

- Harel Rotem

- Chairman of the Board
- CEO
- CFO
- VP International Sales
- VP R&D
- VP Clinical Development & Regulatory Affairs
- VP Cosmetic Division and Consumer Products

Recent Events

- Feb 2 2009 Syneron Board Appoints Louis Scafuri as New Chief Executive Officer
- Dec 9 2008 Syneron Unveils Elegant, Portable eMatrix™ Skin Resurfacing System
- Nov 19 2008 Syneron Medical Announces the Establishment of Syneron China
- Nov 04 2008 Syneron Acquires San Diego-Based Inlight Corp.
- Sep 23 2008 Syneron Receives FDA Clearance for Versatile Matrix RF(TM) Fractional Ablative Applicator
- Sep 19 2008 Syneron Receives European CE Mark for Versatile Matrix RF(TM) Fractional Ablative Applicator
- Jul 29 2008 Syneron Launches Aesthetic Industry's First Physician Subscription Program for its LipoLite™ Laser-Assisted Lipolysis Device
- May 1 2008 Syneron's LipoLite™ Minimally Invasive Laser-Assisted Lipolysis Receives FDA Clearance

Product Platform

eLight



a complete elōs facial solution

eLaser



Diode laser elōs technology

eMax



a complete aesthetic elōs workstation

VelaShape



a cellulite and body shaping solution

LipoLite



laser-assisted lipolysis

eMatrix



Portable skin resurfacing system

Syneron's addressable market has grown 20 fold from 50,000 potential users in the mid 90's to more than 1,000,000 potential users now

For more information and on on-line investor kit: www.syneron.com/investors